Johnny John Email

Sr VP Clinical Development & Medical Affairs . Delcath Systems

New York, NY

Location

j****@delcath.com

Primary Email

LinkedIn

Current Roles

Employees:
74
Revenue:
$7.5M
About
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe
Delcath Systems Address
1633 Broadway
New York, NY
United States

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.